The startup develops vascular access devices utilizing a novel hydrogel material that minimizes thrombus accumulation, infection, and phlebitis without coatings or additives. This technology enhances catheter dwell time and reduces the risk of blood clots, addressing significant complications in intravenous therapy.
Funding
$54.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vascular access devices often lead to complications such as thrombus accumulation, infection, and phlebitis, which can interrupt treatment and increase healthcare costs. Existing solutions may rely on coatings or additives that can degrade over time, reducing their effectiveness. These complications contribute to unnecessary device replacements, additional needle sticks, and delays in patient care.
Solution
Access Vascular develops vascular access devices using a novel, patented hydrophilic biomaterial featuring MIMIX technology, designed to minimize thrombus accumulation and associated complications without coatings or additives. The MIMIX technology mimics the body's natural chemistry, reducing the foreign body response and preventing complications like occlusions and replacements. This approach results in statistically significant reduction in complications compared to standard polyurethane catheters. The HydroPICC and HydroMID devices offer short- or long-term peripheral access to the central venous system, providing a better patient experience and potential cost savings for healthcare facilities.
Target Audience
The primary target audience includes clinicians, hospitals, and healthcare facilities seeking to reduce vascular access complications, improve patient outcomes, and lower healthcare costs associated with intravenous therapy.
Features
- Novel hydrophilic biomaterial featuring MIMIX technology designed to reduce thrombosis
- Statistically significant reduction in complications compared to standard polyurethane catheters
- No coatings, fillers, or surface modifications
- HydroPICC: Peripherally inserted central catheter available in 4 French single lumen and 5 French dual lumen configurations
- HydroMID: Midline catheter available in 4 French single lumen configuration
- Demonstrated an average of 97% less thrombus accumulation on its surface compared to standard polyurethane catheters in in vitro testing
- HydroMID demonstrated 6x fewer complications than standard polyurethane catheters in a retrospective clinical study
- HydroPICC reduced the average tracking force vs a standard polyurethane catheter by 84% in in vitro testing